Empagliflozin FDA Approved for Prevention of Cardiovascular Death

In an unprecedented move, the US FDA approved the SGLT-2 inhibitor empagliflozin for the prevention of cardiovascular death in patients with type 2 diabetes and coexisting cardiovascular disease (CVD). Empagliflozin was first approved in 2014 for the treatment of type 2 diabetes and later demonstrated cardiovascular risk reduction in the EMPA-REG trial. Specifically, treatment with […]

SGLT-2 Inhibitor Reduces CV Risk and Shows Superiority in CV Outcomes Trial

Results of the EMPA-REG OUTCOME trial have shown that the SGLT2-inhibitor empagliflozin has met the primary cardiovascular (CV) outcomes endpoint and demonstrated superiority, reducing the risk of myocardial infarction, stroke, and CV death in more than 7000 adults with type 2 diabetes at high CV risk. Patients in the study were given either low- or […]